This international multicenter randomized controlled study enrolled 572 treatment‐naïve metastatic NSCLC patients preselected for PD‐L1 positivity (tumor cell [TC] or immune cell [IC] ≥ 1% via VENTANA PD‐L1 [SP142] assay), randomly assigning them to either atezolizumab monotherapy (1200 mg q3w) or platinum‐based doublet chemotherapy [20]. This evidence concerns the gene CD274 and neoplasm.